Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025

Reuters

昨天

Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025

Viatris Inc., a global healthcare company, has announced the presentation of five data abstracts from its Phase 3 program evaluating a novel fast-acting formulation of meloxicam, known as MR-107A-02, at the PAINWeek 2025 national conference in Las Vegas. Scheduled from September 2-5, 2025, the presentations will cover the efficacy, safety, and opioid use reduction data in moderate-to-severe acute surgical pain models, specifically in herniorrhaphy and bunionectomy surgeries. Additionally, pharmacokinetics data will be shared. The presentations will include live abstract sessions on September 4, 2025, and all accepted scientific abstracts are available on the PAINWeek website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42356) on August 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556811938"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556811938\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2556811938?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556811938","market":"us","top_or_hot":-1,"title":"Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a>, a global healthcare company, has announced the presentation of five data abstracts from its Phase 3 program evaluating a novel fast-acting formulation of meloxicam, known as MR-107A-02, at the PAINWeek 2025 national conference in Las Vegas. Scheduled from September 2-5, 2025, the presentations will cover the efficacy, safety, and opioid use reduction data in moderate-to-severe acute surgical pain models, specifically in herniorrhaphy and bunionectomy surgeries. Additionally, pharmacokinetics data will be shared. The presentations will include live abstract sessions on September 4, 2025, and all accepted scientific abstracts are available on the PAINWeek website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42356) on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-01 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a>, a global healthcare company, has announced the presentation of five data abstracts from its Phase 3 program evaluating a novel fast-acting formulation of meloxicam, known as MR-107A-02, at the PAINWeek 2025 national conference in Las Vegas. Scheduled from September 2-5, 2025, the presentations will cover the efficacy, safety, and opioid use reduction data in moderate-to-severe acute surgical pain models, specifically in herniorrhaphy and bunionectomy surgeries. Additionally, pharmacokinetics data will be shared. The presentations will include live abstract sessions on September 4, 2025, and all accepted scientific abstracts are available on the PAINWeek website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42356) on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDLbWJ2NR:1","article_id":"2556811938","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556811938","pubTimestamp":1754056850,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viatris Inc., a global healthcare company, has announced the presentation of five data abstracts from its Phase 3 program evaluating a novel fast-acting formulation of meloxicam, known as MR-107A-02, at the PAINWeek 2025 national conference in Las Vegas. Scheduled from September 2-5, 2025, the presentations will cover the efficacy, safety, and opioid use reduction data in moderate-to-severe acute surgical pain models, specifically in herniorrhaphy and bunionectomy surgeries. Additionally, pharmacokinetics data will be shared. The presentations will include live abstract sessions on September 4, 2025, and all accepted scientific abstracts are available on the PAINWeek website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4583":"猴痘概念","BK4585":"ETF&股票定投概念","BK4007":"制药","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","VTRS":"Viatris Inc."},"translate_title":"Viatris在2025年PAINWeek上公布了速效美洛昔康治疗急性手术疼痛的有希望的3期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025\n    \n\nViatris Inc., a global healthcare company, has announced the presentation of five data abstracts from its Phase 3 program evaluating a novel fast-acting formulation of meloxicam, known as MR-107A-02, at the PAINWeek 2025 national conference in Las Vegas. Scheduled from September 2-5, 2025, the presentations will cover the efficacy, safety, and opioid use reduction data in moderate-to-severe acute surgical pain models, specifically in herniorrhaphy and bunionectomy surgeries. Additionally, pharmacokinetics data will be shared. The presentations will include live abstract sessions on September 4, 2025, and all accepted scientific abstracts are available on the PAINWeek website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42356) on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}